Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH
can be classified as benign prostatic hyperplasia (BPH), or prostate cancer (PCa) based on …

Noncoding RNAs (ncRNAs) have attracted much attention in cancer research field. They are
involved in cellular development, proliferation, differentiation and apoptosis. The …

METHODS In this study, we applied an lncRNA microarray to screen the potential biomarker
for HCC. The multi-stage validation and risk score formula detection was used for validation …

Most forms of castration-resistant prostate cancer (CRPC) are dependent on the androgen
receptor (AR) for survival. While, enzalutamide provides a substantial survival benefit, it is …

Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the
second leading cause of cancer-related death affecting men in the United States. Moreover …

Prostate cancer (PCa) is known as one of the most prevalent malignancies globally and is
not yet curable owing to its progressive nature. It has been well documented that Genetic …

Background: The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led
to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early …

Prostate cancer (PCa) is the second most common diagnosed malignant disease in men
worldwide. Although serum PSA test dramatically improved the early diagnosis of PCa, it …

Prostate cancer (PCa) is the most common malignant tumor and the second leading cause
of cancer-related mortality in men worldwide. Despite significant advances in PCa therapy …

Prostate cancer is the second most common cancer in men in the United States, and racial
disparities are greatly observed in the disease. Specifically, African American (AA) patients …